Philippe Calais

Philippe Calais has more than 35 years’ experience managing across functions of the drug development chain from discovery through commercialization, partnership, financing, and IPOs. Prior to joining MatriSys, Philippe served as Director and Interim Chief Executive Officer of CohBar. He has more than 23 years of experience in North America and 13 years in Europe managing companies in broad therapeutic spaces including oncology, anti-infectives, cardiovascular, dermatology, and CNS. He currently serves as Chairman of the Board of Directors at Phileas Pharma and TransCode Therapeutics and is an affiliate research professor in the Center for Molecular Biology & Biotechnology in the Charles E. Schmidt College of Science of Florida Atlantic University. Philippe holds a Bachelor’s degree in Pharmacy and a Doctorate in Pharmacy from the University François-Rabelais in Tours, France.